Topical therapy with negative allosteric modulators of the calcium-sensing receptor (calcilytics) for the management of asthma: the beginning of a new era?

Footnotes

This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.

Conflict of Interest: Chris J Corrigan, Jeremy PT Ward and Daniela Riccardi hold a patent for the development of calcium receptor antagonists for the treatment of inflammatory lung disease (https://patents.google.com/patent/WO2014049351A1/en) and Daniela Riccardi and Polina L Yarova have a pending Composition of Matter patent currently undergoing filing for development of new chemical entities: “Novel calcilytics for pulmonary disease” (IP from NCE GB1719023.2). These authors and the remaining authors Luke J Janssen, Tak H Lee and Sun Ying declare no other conflicts of interest relevant to the content of this manuscript, including grants or contracts from any other entity, royalties or licences, consulting fees, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events, payment for expert testimony, support for attending meetings and/or travel, participation on a Data Safety Monitoring Board or Advisory Board, leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid, stock or stock options, receipt of equipment, materials, drugs, medical writing, gifts or other services or other financial or non-financial interests.

• Received April 19, 2021.
• Accepted December 15, 2021.

• Copyright ©The authors 2022. For reproduction rights and permissions contact permissions{at}ersnet.org